Compounders Research Compare

MoonLake Immunotherapeutics(MLTX)

Biotechnology · Zug, ZG

$11.00-0.38 (-3.34%)

Delayed quote: Oct 6, 2026, 2:00 PM EDT

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics operates as a clinical-stage biopharmaceutical company, concentrating its efforts on discovering and developing novel therapies. The company's primary focus is the advancement of Sonelokimab, an innovative, investigational Nanobody-based treatment engineered to target inflammatory conditions. Currently, Sonelokimab is undergoing mid-stage (Phase II) clinical trials for a range of inflammatory diseases, including hidradenitis suppurativa, psoriatic arthritis, and both ankylosing spondylitis and radiographic axial spondyloarthritis. Established in 2021, MoonLake Immunotherapeutics is based in Zug, Switzerland.

Zug, ZG

130 employees

www.moonlaketx.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Jorge Santos da Silva

View full financials

Earnings Yield: N/A

Basis: Unrounded diluted TTM EPS / FMP quote price × 100. Source: stored company filings and market data; unavailable inputs remain N/A.

The earnings yield is N/A as of 2026-10-06T18:03:47.691Z.

Stored calculation inputs

Calculation as of: 2026-10-06T18:03:47.691Z.

Quote observation: 2026-10-06T18:00:24.000Z. Amounts in USD. The price header may show a later quote.

Unrounded diluted TTM EPS · period ending 2026-06-30: -3.85
Quote price: 11

FMP input reference: 69a1d57d3f318828ebe19021960b74268097702d5d6050a421f3255bba496414

P/E Ratio|FCF Yield|Dividend Yield|All Metrics

MLTX Earnings Yield Metrics

EARNINGS YIELD

N/A

MLTX Competitors' Earnings Yield

MoonLake Immunotherapeutics

Current

Market Cap

$925.27M

Earnings Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CeriBell, Inc.

Market Cap

$930.12M

Earnings Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Kura Oncology, Inc.

Market Cap

$938.44M

Earnings Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

HealthStream, Inc.

Market Cap

$913.71M

Earnings Yield

2.29%

TTM Avg

2.73%

3Y Avg

2.26%

5Y Avg

1.85%

Odyssey Therapeutics, Inc.

Market Cap

$901.55M

Earnings Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Seaport Therapeutics, Inc. Common Stock

Market Cap

$943.74M

Earnings Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Savara Inc.

Market Cap

$950.86M

Earnings Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Bioventus Inc.

Market Cap

$899.69M

Earnings Yield

5.80%

TTM Avg

3.29%

3Y Avg

3.29%

5Y Avg

3.62%

Aktis Oncology, Inc.

Market Cap

$969.83M

Earnings Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Pacira BioSciences, Inc.

Market Cap

$973.18M

Earnings Yield

1.42%

TTM Avg

1.18%

3Y Avg

2.75%

5Y Avg

2.30%

NAME	MARKET CAP	EARNINGS YIELD	TTM	3Y	5Y
MoonLake Immunotherapeutics (MLTX)	$925.27M	N/A	N/A	N/A	N/A
CeriBell, Inc. (CBLL)vs ›	$930.12M	N/A	N/A	N/A	N/A
Kura Oncology, Inc. (KURA)vs ›	$938.44M	N/A	N/A	N/A	N/A
HealthStream, Inc. (HSTM)vs ›	$913.71M	2.29%	2.73%	2.26%	1.85%
Odyssey Therapeutics, Inc. (ODTX)vs ›	$901.55M	N/A	N/A	N/A	N/A
Seaport Therapeutics, Inc. Common Stock (SPTX)vs ›	$943.74M	N/A	N/A	N/A	N/A
Savara Inc. (SVRA)vs ›	$950.86M	N/A	N/A	N/A	N/A
Bioventus Inc. (BVS)vs ›	$899.69M	5.80%	3.29%	3.29%	3.62%
Aktis Oncology, Inc. (AKTS)vs ›	$969.83M	N/A	N/A	N/A	N/A
Pacira BioSciences, Inc. (PCRX)vs ›	$973.18M	1.42%	1.18%	2.75%	2.30%

Earnings Yield vs P/E Ratio

Earnings Yield

N/A

EPS ÷ Price

P/E Ratio

N/A

Price ÷ EPS

Formula: Earnings Yield = (EPS / Price) × 100

Earnings Yield is simply the inverse of P/E. A P/E of 20 equals a 5% earnings yield.

How earnings yield is used:

It expresses earnings relative to share price as a percentage
It can be compared with FCF yield and dividend yield
It can be compared with bond yields because both are percentages
It is mathematically the inverse of the P/E ratio

Earnings Yield Formula & Definition

Earnings Yield = EPS (TTM) / Share Price

Earnings yield is the inverse of the PE ratio, expressing trailing earnings as a percentage of price. Higher is cheaper.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

P/E Ratio FCF Yield Dividend Yield All Metrics